Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, IgA nephropathy (IgAN). In a phase 3 trial of adults who are at risk of ...
Ultomiris (ravulizumab-cwvz) is a brand-name injection that’s prescribed for certain rare diseases. As with other drugs, Ultomiris can cause side effects, such as upper respiratory tract infection and ...
(Alliance News) - AstraZeneca PLC on Saturday announced new data on its kidney disease treatment Ultomiris. The Cambridge, England-based pharmaceutical company said in I CAN phase 3 trial data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results